What is Cybin?
Founded in 2019 and headquartered in Canada, Cybin operates as a leading ethical biotechnology company dedicated to creating safe and effective therapeutics for a range of mental health issues. The company leverages a network of world-class partners and internationally recognized scientists. Cybin's operational footprint extends across Canada, the United States, the United Kingdom, the Netherlands, and Ireland. Its core mission is to advance Psychedelics to Therapeutics through proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches, and comprehensive treatment regimens.
How much funding has Cybin raised?
Cybin has raised a total of $80M across 2 funding rounds:
Share Placement
$30M
Debt
$50M
Share Placement (2023): $30M, investors not publicly disclosed
Debt (2025): $50M, investors not publicly disclosed
What's next for Cybin?
The recent major strategic investment signals a pivotal growth phase for Cybin, likely enabling the company to accelerate its research and development pipelines, expand clinical trials, and scale its operational infrastructure. This significant backing suggests confidence from investors in Cybin's unique approach to mental health treatment and its potential to disrupt the pharmaceutical landscape. The company is well-positioned to further its mission of transforming mental healthcare through innovative psychedelic-based therapies.
See full Cybin company page
